Angiodynamics (ANGO) Common Equity (2011 - 2026)

Angiodynamics (ANGO) has reported Common Equity for 16 consecutive years, with $170.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 6.64% year-over-year to $170.8 million; the trailing twelve-month figure through May 2026 stood at $170.8 million (down 6.64% YoY), and the FY2026 full-year result was $170.8 million, down 6.64% from the prior year.
• Common Equity declined to $170.8 million in Q2 2026 per ANGO's latest filing, from $173.4 million in the prior quarter.
• Across five years, Common Equity topped out at $429.7 million in Q1 2022 and bottomed at $170.8 million in Q2 2026.
• Historically, Common Equity has averaged $286.5 million across 5 years, with a median of $212.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Common Equity rose 3.32% in 2023, then tumbled 54.05% in 2024.
• Over 5 years, Common Equity stood at $408.0 million in 2022, then fell by 1.65% to $401.2 million in 2023, then sank by 53.45% to $186.8 million in 2024, then decreased by 5.59% to $176.3 million in 2025, then decreased by 3.12% to $170.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $170.8 million, $173.4 million, and $176.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.